Author: Ha, Seok Gyun; Oh, Kyung Jin; Ko, Kwang-Pil; Sun, Yong Han; Ryoo, Eell; Tchah, Hann; Jeon, In Sang; Kim, Hyo Jeong; Ahn, Jung Min; Cho, Hye-Kyung
Title: Therapeutic Efficacy and Safety of Prolonged Macrolide, Corticosteroid, Doxycycline, and Levofloxacin against Macrolide-Unresponsive Mycoplasma pneumoniae Pneumonia in Children Document date: 2018_9_18
ID: yrbo0hdk_29
Snippet: The incidence of macrolide resistance of MP has recently increased and has been related to life-threatening or refractory MP pneumonia in children. 16 Several studies on macrolide and alternative treatments for MRMP have been reported. However, data on their therapeutic efficacy and safety in children are still limited. We compared the therapeutic efficacy of PMC, CST, DXC, and LFX against macrolide-unresponsive MP pneumonia and collected data ab.....
Document: The incidence of macrolide resistance of MP has recently increased and has been related to life-threatening or refractory MP pneumonia in children. 16 Several studies on macrolide and alternative treatments for MRMP have been reported. However, data on their therapeutic efficacy and safety in children are still limited. We compared the therapeutic efficacy of PMC, CST, DXC, and LFX against macrolide-unresponsive MP pneumonia and collected data about their safety in children. Most of the patient achieved defervescence within 48 hours after the secondary treatment and any side effect was not observed in the CST, DXC, and LFX groups. However, TTD after initial macrolide treatment did not differ significantly between the PMC, CST, DXC, and LFX groups.
Search related documents:
Co phrase search for related documents- initial macrolide treatment and lfx DXC CST PMC therapeutic efficacy: 1
- initial macrolide treatment and lfx group: 1
- initial macrolide treatment and lfx group dxc: 1
- initial macrolide treatment and macrolide treatment: 1, 2, 3, 4, 5, 6, 7
- initial macrolide treatment and macrolide unresponsive: 1
- initial macrolide treatment and macrolide unresponsive MP pneumonia: 1
- lfx DXC CST PMC therapeutic efficacy and macrolide treatment: 1
- lfx DXC CST PMC therapeutic efficacy and macrolide unresponsive: 1
- lfx DXC CST PMC therapeutic efficacy and macrolide unresponsive MP pneumonia: 1
- lfx group and macrolide treatment: 1
- lfx group dxc and macrolide treatment: 1
- macrolide resistance and MP macrolide resistance: 1, 2, 3, 4
- macrolide treatment and MP macrolide resistance: 1, 2, 3
- macrolide unresponsive and MP macrolide resistance: 1, 2
Co phrase search for related documents, hyperlinks ordered by date